• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.

作者信息

Dupré Anastasia, Michot Jean-Marie, Schoeffler Amélie, Frumholtz Laure, Baroudjian Barouyr, Delyon Julie, Lebbe Céleste, Lambotte Olivier

机构信息

Service de Médecine Interne et d'Immunologie Clinique, AP-HP Université Paris-Saclay, Hôpital Bicêtre, Villejuif, France.

Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.

出版信息

Br J Haematol. 2020 Jun;189(5):985-992. doi: 10.1111/bjh.16630. Epub 2020 Apr 3.

DOI:10.1111/bjh.16630
PMID:32243578
Abstract
摘要

相似文献

1
Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.免疫检查点抑制剂相关噬血细胞性淋巴组织细胞增生症：一项描述性病例研究及文献综述
Br J Haematol. 2020 Jun;189(5):985-992. doi: 10.1111/bjh.16630. Epub 2020 Apr 3.
2
First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.卡博替尼联合检查点抑制剂继发噬血细胞性淋巴组织细胞增生症的首例病例。
Rheumatology (Oxford). 2021 May 14;60(5):e167-e168. doi: 10.1093/rheumatology/keaa750.
3
Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.检查点抑制剂治疗所致继发性噬血细胞性淋巴组织细胞增生症
Eur J Cancer. 2019 Jul;115:84-87. doi: 10.1016/j.ejca.2019.04.026. Epub 2019 May 23.
4
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.单药或双药免疫检查点抑制剂作为晚期黑色素瘤的辅助治疗
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
5
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.黑色素瘤患者接受伊匹单抗+纳武单抗治疗后发生严重噬血细胞性淋巴组织细胞增生症。
J Immunother Cancer. 2018 Jul 16;6(1):73. doi: 10.1186/s40425-018-0384-0.
6
Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.免疫检查点抑制剂相关性结肠炎损伤形态学模式的药物特异性变化。
Histopathology. 2021 Mar;78(4):532-541. doi: 10.1111/his.14248. Epub 2020 Nov 22.
7
Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.噬血细胞性淋巴组织细胞增生症作为联合抗 PD-1 和抗 CTLA-4 检查点抑制剂免疫治疗转移性黑色素瘤的并发症，以及重新使用单药抗 PD-1 免疫治疗的结果。
BMJ Case Rep. 2022 Aug 10;15(8):e251052. doi: 10.1136/bcr-2022-251052.
8
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.免疫检查点抑制剂相关性肉瘤病：一种通常良性的疾病，不需要停止免疫治疗。
Eur J Cancer. 2021 Nov;158:208-216. doi: 10.1016/j.ejca.2021.05.041. Epub 2021 Aug 25.
9
A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.1例转移性黑色素瘤患者因免疫检查点抑制剂诱发的过敏性紫癜。
Eur J Cancer. 2020 Nov;139:169-172. doi: 10.1016/j.ejca.2020.08.005. Epub 2020 Sep 29.
10
Sicca syndrome following immune checkpoint inhibition.免疫检查点抑制后干燥综合征。
Clin Immunol. 2020 Aug;217:108497. doi: 10.1016/j.clim.2020.108497. Epub 2020 Jun 9.

引用本文的文献

1
Preoperative pembrolizumab‑induced hemophagocytic lymphohistiocytosis in a patient with breast cancer: A case report.一名乳腺癌患者术前使用帕博利珠单抗诱发噬血细胞性淋巴组织细胞增生症：病例报告
Oncol Lett. 2025 Jan 9;29(3):136. doi: 10.3892/ol.2025.14882. eCollection 2025 Mar.
2
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.胶质母细胞瘤患者中与免疫治疗相关的继发性噬血细胞增多症：对细胞因子导向治疗的反应
Immunotherapy. 2025 Jan;17(1):11-17. doi: 10.1080/1750743X.2025.2451604. Epub 2025 Jan 15.
3
Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.
噬血细胞性淋巴组织细胞增生症：血液系统恶性肿瘤和实体肿瘤相关噬血细胞性淋巴组织细胞增生症。
Adv Exp Med Biol. 2024;1448:429-440. doi: 10.1007/978-3-031-59815-9_29.
4
A case report of hemophagocytic lymphohistiocytosis induced by toripalimab plus chemoradiotherapy in cervical cancer.托法替布联合放化疗诱发宫颈癌噬血细胞性淋巴组织细胞增生症一例报告
Heliyon. 2024 Jun 28;10(13):e33816. doi: 10.1016/j.heliyon.2024.e33816. eCollection 2024 Jul 15.
5
A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma.阿替利珠单抗治疗肺腺癌致噬血细胞性淋巴组织细胞增生症和脑膜炎一例报告
Cureus. 2024 Apr 14;16(4):e58253. doi: 10.7759/cureus.58253. eCollection 2024 Apr.
6
Fever of unknown origin associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的不明原因发热。
Front Immunol. 2024 Mar 12;15:1364128. doi: 10.3389/fimmu.2024.1364128. eCollection 2024.
7
Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report.复发经典型霍奇金淋巴瘤患者联合使用维布妥昔单抗和纳武利尤单抗后出现严重细胞因子释放综合征和噬血细胞性淋巴组织细胞增生症（HLH）样综合征：一例报告
J Blood Med. 2024 Jan 24;15:29-34. doi: 10.2147/JBM.S444004. eCollection 2024.
8
Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management.罕见的免疫相关不良事件（irAEs）：诊断和管理方法。
Pharmaceut Med. 2024 Jan;38(1):25-38. doi: 10.1007/s40290-023-00508-5. Epub 2024 Jan 9.
9
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.帕博利珠单抗联合贝伐珠单抗治疗宫颈癌后噬血细胞性淋巴组织细胞增生症：病例报告及系统评价。
BMC Geriatr. 2024 Jan 8;24(1):32. doi: 10.1186/s12877-023-04625-3.
10
Checkpoint inhibitors.检查点抑制剂。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):209-215. doi: 10.1182/hematology.2023000523.